Eine Studie zur Bewertung unerwünschter Ereignisse und der Art und Weise, wie intravenös (IV) infundiertes Telisotuzumab Vedotin (ABBV-399) als Monotherapie bei erwachsenen Teilnehmern mit zuvor behandeltem nicht-Plattenepithelkarzinom (NSCLC) durch den Körper wandert
Eine offene, randomisierte, globale Phase-2-Studie mit zwei Telisotuzumab-Vedotin-Therapien bei Patienten mit zuvor behandeltem c-Met-überexprimierendem, EGFR-Wildtyp-, lokal fortgeschrittenem/metastasiertem, nicht-Plattenepithelkarzinom, nicht-kleinzelligem Lungenkrebs
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-Mail: abbvieclinicaltrials@abbvie.com
Studienorte
-
-
-
São Paulo, Brasilien, 01323-020
- Rekrutierung
- Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
-
-
Ceará
-
Fortaleza, Ceará, Brasilien, 60810-180
- Rekrutierung
- Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
-
-
Paraná
-
Curitiba, Paraná, Brasilien, 80510-130
- Rekrutierung
- Ictrials Pesquisa E Desenvolvimento /ID# 276681
-
-
Pará
-
Belém, Pará, Brasilien, 66063-495
- Rekrutierung
- Cto - Centro De Tratamento Oncologico /ID# 276699
-
-
Pernambuco
-
Recife, Pernambuco, Brasilien, 50040-000
- Rekrutierung
- Hospital De Cancer De Pernambuco /ID# 276104
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasilien, 59075-740
- Rekrutierung
- Liga Norte Riograndense Contra O Cancer /ID# 273183
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brasilien, 98700-000
- Rekrutierung
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasilien, 88020-210
- Rekrutierung
- Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 101149
- Rekrutierung
- Beijing Chest Tumor Hospital /ID# 271935
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Rekrutierung
- Fujian Province Cancer Hospital /ID# 276178
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Rekrutierung
- Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Rekrutierung
- Harbin Medical University Cancer Hospital /ID# 271665
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Rekrutierung
- Henan Cancer Hospital /ID# 271927
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Rekrutierung
- Union Hospital - Tongji Medical College /ID# 271668
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Rekrutierung
- The First Affiliated Hospital of Nanchang University /ID# 271666
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- Rekrutierung
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
-
-
Shandong
-
Linyi, Shandong, China, 276001
- Rekrutierung
- LinYi Cancer Hospital /ID# 272068
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830011
- Rekrutierung
- Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
-
-
-
-
-
Haifa, Israel, 3109601
- Rekrutierung
- Rambam Health Care Campus- Haifa /ID# 270078
-
Jerusalem, Israel, 9103102
- Abgeschlossen
- Shaare Zedek Medical Center /ID# 270095
-
-
Central District
-
Kefar Sava, Central District, Israel, 4428164
- Rekrutierung
- Meir Medical Center /ID# 270071
-
Petah Tikva, Central District, Israel, 4941492
- Rekrutierung
- Rabin Medical Center. /ID# 270087
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israel, 5265601
- Rekrutierung
- The Chaim Sheba Medical Center /ID# 270068
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 466-8560
- Rekrutierung
- Nagoya University Hospital /ID# 277010
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- Rekrutierung
- National Cancer Center Hospital East /ID# 277056
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8648
- Rekrutierung
- Hokkaido University Hospital /ID# 277014
-
-
Hyōgo
-
Kobe, Hyōgo, Japan, 650-0046
- Rekrutierung
- Kobe Minimally Invasive Cancer Center /ID# 277469
-
-
Kanagawa
-
Sagamihara-shi, Kanagawa, Japan, 252-0375
- Rekrutierung
- Kitasato University Hospital /ID# 277012
-
-
Miyagi
-
Sendai, Miyagi, Japan, 981-0914
- Rekrutierung
- Sendai Kousei Hospital /ID# 277023
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japan, 889-1692
- Rekrutierung
- University of Miyazaki Hospital /ID# 277020
-
-
Okayama-ken
-
Kurashiki-shi, Okayama-ken, Japan, 710-8602
- Rekrutierung
- Kurashiki Central Hospital /ID# 276995
-
-
Shizuoka
-
Fujieda, Shizuoka, Japan, 426-0077
- Rekrutierung
- Fujieda Municipal General Hospital /ID# 277025
-
-
Wakayama
-
Wakayama, Wakayama, Japan, 641-8510
- Rekrutierung
- Wakayama Medical University Hospital /ID# 276997
-
-
-
-
Beograd
-
Belgrade, Beograd, Serbien, 11000
- Rekrutierung
- Institute for Oncology and Radiology of Serbia /ID# 270561
-
Belgrade, Beograd, Serbien, 11080
- Rekrutierung
- Clinical Hospital Center - Bezanijska Kosa /ID# 270558
-
Belgrade, Beograd, Serbien, 11000
- Rekrutierung
- University Clinical Center Serbia /ID# 270808
-
Belgrade, Beograd, Serbien, 11000
- Rekrutierung
- Military Medical Academy /ID# 279873
-
-
Nisavski Okrug
-
Niš, Nisavski Okrug, Serbien, 18300
- Rekrutierung
- University Clinical Center Nis /ID# 270557
-
-
Sremski Okrug
-
Kamenitz, Sremski Okrug, Serbien, 21208
- Rekrutierung
- Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
-
-
Sumadijski Okrug
-
Kragujevac, Sumadijski Okrug, Serbien, 34000
- Rekrutierung
- University Clinical Center Kragujevac /ID# 275773
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, Singapur, 169611
- Rekrutierung
- National Cancer Centre Singapore /ID# 271499
-
Singapore, Central Singapore, Singapur, 119074
- Rekrutierung
- National University Hospital /ID# 271700
-
-
-
-
Arizona
-
Chandler, Arizona, Vereinigte Staaten, 85224
- Rekrutierung
- Ironwood Cancer and Research Center /ID# 276370
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- Rekrutierung
- University of Arkansas for Medical Sciences /ID# 272923
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90067
- Rekrutierung
- Valkyrie Clinical Trials /ID# 271322
-
Los Angeles, California, Vereinigte Staaten, 90025
- Rekrutierung
- Start Los Angeles /ID# 284999
-
Oxnard, California, Vereinigte Staaten, 93030
- Rekrutierung
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06510
- Abgeschlossen
- Yale New Haven Hospital /ID# 271584
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32256
- Rekrutierung
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
-
Ocala, Florida, Vereinigte Staaten, 34474
- Rekrutierung
- Ocala Oncology Center /ID# 273697
-
Pembroke Pines, Florida, Vereinigte Staaten, 33028
- Rekrutierung
- Memorial Hospital West /ID# 270313
-
St. Petersburg, Florida, Vereinigte Staaten, 33701-4732
- Rekrutierung
- Comprehensive Hematology Oncology /ID# 270422
-
St. Petersburg, Florida, Vereinigte Staaten, 33705
- Rekrutierung
- Florida Cancer Specialists - North /ID# 271995
-
West Palm Beach, Florida, Vereinigte Staaten, 33401
- Rekrutierung
- Florida Cancer Specialists - East /ID# 271993
-
-
Georgia
-
Athens, Georgia, Vereinigte Staaten, 30607
- Rekrutierung
- University Cancer and Blood Center /ID# 270969
-
Marietta, Georgia, Vereinigte Staaten, 30060
- Rekrutierung
- Northwest Georgia Oncology Centers /ID# 275374
-
Savannah, Georgia, Vereinigte Staaten, 31404
- Abgeschlossen
- Memorial University Medical Center /ID# 272467
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96819
- Rekrutierung
- Kaiser Permanente Moanalua Medical Center /ID# 272916
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60607
- Rekrutierung
- University of Illinois Hospital and Health Sciences System /ID# 275345
-
Niles, Illinois, Vereinigte Staaten, 60714
- Rekrutierung
- Illinois Cancer Specialists /ID# 274678
-
Peoria, Illinois, Vereinigte Staaten, 61637-0001
- Rekrutierung
- OSF St. Francis Medical Center /ID# 281591
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Springfield Clinic - First /ID# 272576
-
-
Nebraska
-
Lincoln, Nebraska, Vereinigte Staaten, 68506
- Rekrutierung
- Nebraska Hematology-Oncology /ID# 272970
-
Omaha, Nebraska, Vereinigte Staaten, 68130
- Rekrutierung
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
-
-
Nevada
-
Reno, Nevada, Vereinigte Staaten, 89502
- Rekrutierung
- Renown Regional Medical Center /ID# 273535
-
-
New Jersey
-
East Brunswick, New Jersey, Vereinigte Staaten, 08816-4096
- Rekrutierung
- Astera Cancer Care /ID# 272359
-
Teaneck, New Jersey, Vereinigte Staaten, 07666
- Rekrutierung
- Regional Cancer Care Associates /ID# 270783
-
-
New York
-
The Bronx, New York, Vereinigte Staaten, 10461
- Rekrutierung
- Montefiore Medical Center - Einstein Campus /ID# 277169
-
Westbury, New York, Vereinigte Staaten, 11590
- Rekrutierung
- Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
-
-
North Carolina
-
Pinehurst, North Carolina, Vereinigte Staaten, 28374
- Rekrutierung
- FirstHealth of the Carolinas- Speciality Center /ID# 272924
-
-
Ohio
-
Perrysburg, Ohio, Vereinigte Staaten, 43551
- Rekrutierung
- Mercy Health - Perrysburg Cancer Center /ID# 270536
-
Zanesville, Ohio, Vereinigte Staaten, 43701
- Rekrutierung
- Genesis Healthcare System /ID# 273361
-
-
Pennsylvania
-
Sayre, Pennsylvania, Vereinigte Staaten, 18840
- Rekrutierung
- Guthrie Robert Packer Hospital /ID# 270316
-
York, Pennsylvania, Vereinigte Staaten, 17403
- Rekrutierung
- Cancer Care Associates Of York /ID# 270971
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Rekrutierung
- Medical University of South Carolina /ID# 273272
-
Greenville, South Carolina, Vereinigte Staaten, 29607
- Rekrutierung
- Saint Francis Cancer Center - Greenville /ID# 276368
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- SCRI Oncology Partners /ID# 270162
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75246
- Rekrutierung
- Texas Oncology - Dallas - Worth Street /ID# 278947
-
Tyler, Texas, Vereinigte Staaten, 75702
- Rekrutierung
- Texas Oncology - Northeast Texas /ID# 272000
-
-
Utah
-
Ogden, Utah, Vereinigte Staaten, 84405
- Rekrutierung
- Community Cancer Trials Of Utah /ID# 276598
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- Virginia Cancer Specialists - Fairfax /ID# 272004
-
-
Washington
-
Spokane, Washington, Vereinigte Staaten, 99208
- Rekrutierung
- Medical Oncology Associates - Spokane /ID# 277172
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Rekrutierung
- Northwest Medical Specialties Tacoma /ID# 270534
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Projected life expectancy of at least 12 weeks.
- Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
- Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
- Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
- Actionable alterations in genes other than EGFR are permitted.
- Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
- Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.
Exclusion Criteria:
- Adenosquamous or neuroendocrine histology, or sarcomatoid features.
- EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
- Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
- Received prior docetaxel therapy.
- Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
- History of other malignancies except those stated in the protocol.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
- Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
- Major surgery within 21 days prior to randomization.
- Clinically significant condition(s) including but not limited to those listed in the protocol.
- Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
- Grade >= 2 edema or lymphedema.
- Grade >= 2 ascites or pleural effusion.
- Grade >= 2 neuropathy.
- Active uncontrolled bacterial or viral infection.
- Active corneal disorder.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Telisotuzumab Vedotin Dose A
Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Andere Namen:
|
|
Experimental: Telisotuzumab Vedotin Dose B
Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Andere Namen:
|
|
Experimental: Telisotuzumab Vedotin Dose C
Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
Zeitfenster: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
Zeitfenster: Up to Approximately 3 Years
|
ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
Zeitfenster: Up to Approximately 3 Years
|
Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2) |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
Zeitfenster: Up to Approximately 3 Years
|
Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
Zeitfenster: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Grade 5 Treatment-Emergent AEs
Zeitfenster: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Objective Response (OR) by Blinded Independent Central Review (BICR)
Zeitfenster: Up to Approximately 3 Years
|
OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1. |
Up to Approximately 3 Years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
Zeitfenster: Up to 26 Weeks
|
Concentrations of telisotuzumab vedotin conjugate in serum. |
Up to 26 Weeks
|
|
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
Zeitfenster: Up to 26 Weeks
|
Concentrations of MMAE payload in plasma. |
Up to 26 Weeks
|
|
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
Zeitfenster: Up to 26 Weeks
|
Percentage of participants with ADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
Zeitfenster: Up to 26 Weeks
|
Percentage of participants with nADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Zeitfenster: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present). |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
Zeitfenster: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants. |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Duration of Response (DoR) by BICR
Zeitfenster: Up to Approximately 3 Years
|
DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Progression-Free Survival (PFS) by BICR
Zeitfenster: Up to Approximately 3 Years
|
PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
Zeitfenster: Up to Approximately 3 Years
|
OS will be defined as the time from randomization to death from any cause. |
Up to Approximately 3 Years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: ABBVIE INC., AbbVie
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- M25-274
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-Sharing-Zeitrahmen
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-Sharing-Zugriffskriterien
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .